LMP744
PreclinicalSmall molecule
LMP744 is one of 6 small molecule programs targeting Recurrent Glioblastoma. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Recurrent Glioblastoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Avastin
RochePhase 2
Keytruda
Merck & Co.Phase 2
Cabometyx
Bristol-Myers SquibbPreclinical
ACT001
NNationwide Children's Hospital
Phase 2
LMP744
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recurrent Glioblastoma1 trial
Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Preclinical·NCT07416188·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LMP744. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNational Cancer Institute (NCI)